VANCOUVER, BRITISH COLUMBIA – June 17, 2025) – AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) today announces that the Company’s board of directors has approved the granting of stock options (the “Options”) exercisable for a total of 4,100,000 common shares to its directors, officers, employees and consultants at
VANCOUVER, BRITISH COLUMBIA – June 5, 2025) – AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) is pleased to report the appointment of Rodger Seccombe as CEO of the Company. Mr. Seccombe currently serves as Chief Technology Officer of Avricore and is the President and Co-Founder of its wholly
VANCOUVER, BRITISH COLUMBIA – June 2, 2025) – AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) reports on its result for the first quarter of 2025 and its progress towards expansion objectives for the balance of the year. For the three months ended March 31, 2025 the Company
VANCOUVER, BC – (GLOBE NEWSWIRE) – January 29, 2025 – Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) today announced its successful integration of HealthTab™ the Company’s cloud-connected, pharmacy-based platform for testing and health data management, with Patients Know Best (PKB), the UK’s leading patient personal health record (PHR). The new partnership
VANCOUVER, British Columbia, November 14, 2024 – Avricore Health Inc. (TSX-V: AVCR) (“Avricore” or the “Company”), a leader in pharmacy-based point-of-care testing solutions, today announces a strategic shift to increase its focus on the rapidly expanding UK healthcare market and begin concluding its Canadian pharmacy partnership with Shoppers Drug Mart.
Vancouver, BC — November 6, 2024 — Avricore Health Inc. (TSX-V: AVCR), a leader in pharmacy-based health technology solutions, proudly announces its placement in Deloitte Canada’s 2024 Technology Fast 50™ Companies-to-Watch category, securing the 8th position with an impressive growth rate of 2738%. This award acknowledges Avricore’s pioneering work in
VANCOUVER, BRITISH COLUMBIA – August 29, 2024) – AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) reports on its mid-year results for 2024 demonstrating the Company’s continued success in maintaining strong growth in revenues while achieving net profitability. In the six months ended June 30, 2024 revenues grew by
VANCOUVER, BRITISH COLUMBIA – June 3, 2024) – AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) reports on results for the first three months of 2024, the first period of net profitability for the Company. The Company realized a comprehensive income of $168,537 for the three months ended March
VANCOUVER, BRITISH COLUMBIA, April 30, 2024 – AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “AVCR”) is pleased to announce its audited results for 2023. The Company nearly doubled its previous record revenues to $3,485,147 while gross profit increased by 163% to $1,203,396. The Company is currently in an early
VANCOUVER, BC – (GLOBE NEWSWIRE) – April 4, 2024 – Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce further expansion of HealthTab™ with Rexall Pharmacy Group ULC (“Rexall”). The Companies have been working closely to develop the best patient approaches and internal workflows to ensure the most successful
